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EDITORIAL COMMENT
Exercise Testing in Heart Failure
Maximal, Submaximal, or Both?*
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Birmingham, Alabama
Heart failure (HF) due to systolic dysfunction is a highly
prevalent and often lethal condition, despite recent advances
in pharmacologic therapy. Cardiac transplantation as a
therapeutic modality is severely limited by organ availability.
Exercise testing has been used for some time to determine
patients’ functional status, to assess response to therapy, to
determine prognosis, and, in those with advanced stages of
disease, to aid in the selection of appropriate candidates for
transplantation. Considerable controversy persists, however,
about what type of exercise protocol best predicts prognosis,
how results from different types of exercise testing relate to
each other, and which specific exercise parameters have the
most prognostic utility. Recommendations for prognostica-
tion have ranged from simple dichotomous classifications of
oxygen consumption (VO2) above or below certain cut-off
values to use of complex prognostic scores (1,2).
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Exercise testing and prognosis. Maximal cardiopulmo-
nary exercise testing is considered to be the gold standard of
assessment of functional capacity and prognosis in patients
with HF. Numerous studies document a relationship be-
tween maximal or peak VO2 adjusted for body weight or lean
body mass and subsequent mortality (1–8). This relation-
ship is independent of routinely recorded clinical patient
characteristics known to influence prognosis, such as age,
gender, etiology of HF, left ventricular ejection fraction, or
New York Heart Association classification, but it may no
longer be significant when neurohumoral measures are
added to the models (7,8). Different investigators have
recommended different threshold values of peak VO2 for
prognostic classification (1,3–5). It is thus clear that there is
no single value that discriminates between “good” and
“poor” prognosis and that it may be better to use peak VO2
as a continuous variable. Percent predicted VO2, by virtue of
adjusting for age, weight, and gender, may be an even better
indicator of prognosis than peak VO2, especially among
women (9,10). Many other parameters that can be directly
measured during traditional cardiopulmonary exercise test-
ing or can be derived from measured parameters also relate
to prognosis, including: exercise duration and workload; the
ventilatory response (expressed as the slope of minute
ventilation and carbon dioxide output); estimates of cardiac
power (peak VO2 multiplied by systolic blood pressure
[BP]); chronotropic response and heart rate recovery; and
time course of recovery of oxygen uptake after exercise (11).
These may provide incremental value when added to mea-
surement of peak VO2, but their role in the routine clinical
assessment of patients remains unclear.
Maximal cardiopulmonary exercise testing is often diffi-
cult for patients (especially those who are very ill, severely
deconditioned, or elderly), equipment for testing is expen-
sive and requires regular maintenance, special expertise is
required for the interpretation of the exercise studies, and
the maximal exercise performed does not relate to patients’
day to day activities. Maximal cardiopulmonary exercise
testing, thus, may not be suited for many outpatient
settings. Submaximal exercise testing has been suggested as
an alternative. The 6-min walk test as originally described
by Guyatt et al. (12) has been widely used to assess
submaximal exercise capacity in patients with HF. Its role in
assessment of prognosis remains controversial. Several re-
search groups have shown that the 6-min walk test predicts
morbidity and mortality in patients with varying severity of
HF, whereas other investigators found VO2 measurement to
be superior or could not demonstrate any relationship
between walked distance and prognosis (13–19). Differences
in walking protocol, patient selection, and length of
follow-up likely account for some of this heterogeneity.
Measurement of VO2 during the 6-min walk test has shown
that many individuals with more advanced HF achieve
anaerobic threshold and that VO2 during the walk is on
average only 15% lower than during maximal testing (20).
Submaximal testing may thus be sufficient and preferable for
patients with very poor exercise capacity, whereas traditional
maximal exercise testing may better discriminate prognosis
among patients with more preserved functional capacity.
The current study. In this issue of the Journal, Rickli et al.
(21) suggest that submaximal and maximal cardiopulmonary
exercise testing can be easily combined in a single test and
that such combined testing provides more powerful prog-
nostic information in patients with HF than either test
alone. They evaluated exercise test results and outcomes in
202 patients (86% men) who had been referred to their
clinic for possible cardiac transplantation. All patients un-
derwent a two-stage exercise test (6 min of walking on a
treadmill at 1.0 mph with an elevation of 6%, followed by
graded exercise testing with gas exchange analysis with
workload increase of approximately 0.15 W/kg body
weight/min until exhaustion). Mean follow-up was 873
days. Impaired oxygen kinetics during submaximal steady
state exercise expressed as a mean response time50 s, peak
VO2  50% predicted, and resting systolic BP  105 mm
Hg provided complementary prognostic information. Pa-
tients with none or one of these risk factors had a one-year
event rate of 3%; those with two risk factors had a one-year
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event rate of 33%; and among the 13 patients with all three
risk factors, the one-year event rate was 59%. The prognos-
tic utility of these factors was apparent both in patients
receiving and in those not receiving therapy with
beta-blockers.
Slowed oxygen uptake kinetics during the early stages of
exercise in patients with circulatory abnormalities were first
reported in the 1920s and have been confirmed by several
groups of investigators since (22–26). Mean response time
and oxygen deficit measured during submaximal steady state
exercise on one hand and peak VO2 on the other correlate
with patients’ symptoms, but they correlate only moderately
with each other (26). Measurement of mean response time
is likely to be more reproducible than measurement of peak
VO2 because it is not dependent on patient effort and may be
more closely related to functional limitations during activi-
ties of daily living. Mean response time appears to be more
closely related to a patient’s neurohormonal status (e.g.,
levels of norepinephrine, atrial natriuretic factor, brain
natriuretic peptide) than peak VO2 (26). This close correla-
tion with neurohumoral activation may in part account for
its prognostic utility.
Zugck et al. (27) described the impact of beta-blockade
on the prognostic utility of variables customarily used for
risk stratification in HF. Peak VO2 was predictive both in
patients receiving and in those not receiving beta-blocker
therapy, but those with peak VO2 below 14 ml/kg/min who
were receiving beta-blocker therapy had a prognosis indis-
tinguishable from those with higher VO2 who did not
receive beta-blocker therapy. Beta-blockade would also be
expected to affect the prognostic utility of submaximal
exercise parameters because it slows oxygen uptake kinetics
(25). Rickli et al. (21), in the current study, found similar
prognostic value of their combined assessment of prolonged
mean response time, lower peak oxygen uptake, and low
systolic BP both in patients receiving and in those not
receiving beta-blocker therapy. However, as shown in their
Figure 4, actual survival rates free of urgent transplantation
in the low and intermediate risk groups were substantially
better among those treated with beta-blockers, suggesting
that any risk assessment algorithm used clinically should
stratify on beta-blockade. It is interesting that beta-blocker
therapy did not seem to impact outcome in the highest-risk
group, but this null result may have been a result of the very
small number of patients in this risk stratum.
The current study included few women, few older indi-
viduals, no non-Caucasians, and no patients with non-
cardiac exercise limitations; all patients were specifically
referred for cardiac transplant evaluation. It is thus unclear
whether the results can be applied to other patient groups
and less specialized patient care settings. Furthermore,
submaximal exercise capacity as measured by 6-min walk
distance appears to be greater in European than in Ameri-
can populations at any given severity of HF, possibly
because of different levels of customary physical activity
(28). Activity levels and exercise training have been shown
to alter oxygen uptake kinetics during submaximal exercise
(25). It is thus possible that there are also “transatlantic”
differences in mean response time and oxygen deficits that
may affect the prognostic utility of these variables.
Combining results from submaximal and maximal exer-
cise testing for prognostication is based on sound patho-
physiologic rationale. Such combined testing does not add
to a patient’s burden when compared with traditional
maximal exercise testing and is feasible in any setting in
which cardiopulmonary exercise testing equipment and
trained personnel are available. Although the preliminary
results by Rickli et al. (21) are intriguing, prospective studies
in large, heterogeneous patient populations are needed to
more clearly determine applicability of these preliminary
findings in various patient subgroups and different patient
care settings.
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